下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Analyzing Marker Therapeutics (NASDAQ:MRKR) and Decibel Therapeutics (NASDAQ:DBTX)
分析马克治疗公司(纳斯达克:MRKR)和分贝治疗公司(纳斯达克:DBTX)

Defense World ·  {{timeTz}}

Marker Therapeutics (NASDAQ:MRKR – Get Rating) and Decibel Therapeutics (NASDAQ:DBTX – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

马克治疗公司(纳斯达克:MRKR-GET评级)和分贝治疗公司(纳斯达克:DBTX-GET评级)都是小盘医疗公司,但哪种投资更好?我们将根据这两家公司的机构所有权、收益、风险、股息、估值、分析师建议和盈利能力来比较它们的实力。

Institutional & Insider Ownership

机构与内部人持股

31.8% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 64.0% of Decibel Therapeutics shares are owned by institutional investors. 27.2% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Marker Treateutics 31.8%的股份由机构投资者持有。相比之下,分贝治疗公司64.0%的股份由机构投资者持有。Marker Treateutics 27.2%的股份由内部人士持有。强大的机构持股表明,大型基金管理公司、对冲基金和捐赠基金相信,一只股票有望实现长期增长。

Get
到达
Marker Therapeutics
标记物治疗
alerts:
警报:

Earnings & Valuation

收益与估值

This table compares Marker Therapeutics and Decibel Therapeutics' top-line revenue, earnings per share and valuation.

此表比较了Marker Treeutics和Decombel Treeutics的营收、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marker Therapeutics $1.24 million 36.41 -$41.88 million ($0.52) -1.04
Decibel Therapeutics N/A N/A -$51.82 million ($2.18) -2.04
总收入 价格/销售额比 净收入 每股收益 市盈率
标记物治疗 124万美元 36.41 -4,188万元 ($0.52) -1.04
分贝治疗学 不适用 不适用 -5,182万元 ($2.18) -2.04
Marker Therapeutics has higher revenue and earnings than Decibel Therapeutics. Decibel Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.
标记治疗公司的收入和收益比分贝治疗公司高。分贝治疗公司的市盈率低于Marker治疗公司,这表明它目前是两只股票中更负担得起的一只。

Analyst Ratings

分析师评级

This is a breakdown of recent recommendations for Marker Therapeutics and Decibel Therapeutics, as reported by MarketBeat.

这是MarketBeat报道的标记治疗和分贝治疗最近建议的细目。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics 0 1 0 0 2.00
Decibel Therapeutics 0 0 7 0 3.00
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
标记物治疗 0 1 0 0 2.00
分贝治疗学 0 0 7 0 3.00

Marker Therapeutics currently has a consensus price target of $1.25, suggesting a potential upside of 131.48%. Decibel Therapeutics has a consensus price target of $18.43, suggesting a potential upside of 314.13%. Given Decibel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decibel Therapeutics is more favorable than Marker Therapeutics.

Marker Treateutics目前的共识目标价为1.25美元,暗示潜在上涨131.48%。分贝治疗公司的一致目标价为18.43美元,这意味着潜在的上涨314.13%。鉴于分贝治疗公司更强的共识评级和更高的可能上行空间,分析人士显然认为分贝治疗公司比Marker治疗公司更有利。

Volatility & Risk

波动性与风险

Marker Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Decibel Therapeutics has a beta of -1.48, indicating that its stock price is 248% less volatile than the S&P 500.

Marker Treeutics的贝塔系数为1.28,这表明其股价的波动性比标准普尔500指数高出28%。相比之下,分贝治疗公司的贝塔系数为-1.48,这表明其股价的波动性比标准普尔500指数低248%。

Profitability

盈利能力

This table compares Marker Therapeutics and Decibel Therapeutics' net margins, return on equity and return on assets.

下表比较了马克治疗公司和分贝治疗公司的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Marker Therapeutics N/A -83.20% -58.95%
Decibel Therapeutics N/A -37.06% -29.69%
净利润率 股本回报率 资产回报率
标记物治疗 不适用 -83.20% -58.95%
分贝治疗学 不适用 -37.06% -29.69%

About Marker Therapeutics

关于Marker Treateutics

(Get Rating)

(获取评级)

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Mark Treateutics,Inc.是一家临床阶段的免疫肿瘤学公司,在美国从事各种基于T细胞的免疫疗法和基于多肽的疫苗的开发和商业化,用于治疗血液恶性肿瘤和实体肿瘤适应症。它的多TAA特异性T细胞技术是基于制造非工程肿瘤特异性T细胞,这种T细胞识别多种肿瘤相关抗原,并杀死表达肿瘤相关抗原的肿瘤细胞。该公司的多TAA特异性T细胞疗法包括用于治疗淋巴瘤和各种实体肿瘤的自体T细胞;用于治疗急性髓系白血病和急性淋巴细胞白血病的同种异体T细胞;以及各种适应症的现成产品。它还在开发一种用于治疗乳腺癌和卵巢癌细胞的多肽免疫治疗性疫苗TPIV100/110,以及用于治疗乳腺癌和卵巢癌的处于第二阶段临床试验的TPIV200。该公司成立于1999年,总部设在德克萨斯州休斯敦。

About Decibel Therapeutics

关于分贝疗法

(Get Rating)

(获取评级)

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

分贝治疗公司是一家临床阶段的生物技术公司,致力于发现和开发听力和平衡障碍的变革性治疗方法。该公司的候选产品和计划专注于三个领域,例如,针对先天性单基因听力损失的基因疗法,旨在恢复耳蜗内的功能细胞,以解决单基因突变引起的听力障碍;针对毛细胞再生的基因疗法,旨在取代内耳内丢失的毛细胞,以解决获得性听力损失和平衡障碍;以及耳保护疗法,用于临床开发,以防止接受顺铂化疗的癌症患者的听力损失。该公司的主要基因治疗产品候选产品是DB-OTO,为因耳铁蛋白基因突变而出生时听力严重丧失的人提供听力。该公司还在开发DB-ATO和AAV.201,这是一种基因治疗计划,旨在通过在前庭内再生丢失的毛细胞来恢复双侧前庭病变患者的平衡;DB-020,用于预防顺铂导致的听力损失,该计划正处于1b期临床试验;AAV.103,用于恢复缝隙连接β-2(GJB2)缺陷患者的听力;AAV.104,用于恢复立体素(STRC)缺陷患者的听力;以及耳蜗毛细胞再生计划,这是一种基于AAV的基因治疗方案,利用重新编程因子的细胞选择性表达,将支持细胞转化为外部毛细胞。分贝治疗公司与Regeneron制药公司进行了战略合作,共同开发针对单基因形式先天性耳聋的基因疗法。该公司前身为听力公司,并于2014年4月更名为分贝治疗公司。分贝治疗公司成立于2013年,总部设在马萨诸塞州波士顿。

Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Marker Treateutics Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Marker Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。